JP2019099571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019099571A5 JP2019099571A5 JP2018223465A JP2018223465A JP2019099571A5 JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5 JP 2018223465 A JP2018223465 A JP 2018223465A JP 2018223465 A JP2018223465 A JP 2018223465A JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024045935A JP7767492B2 (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| JP2025182210A JP2026016628A (ja) | 2017-11-29 | 2025-10-29 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017228661 | 2017-11-29 | ||
| JP2017228661 | 2017-11-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045935A Division JP7767492B2 (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019099571A JP2019099571A (ja) | 2019-06-24 |
| JP2019099571A5 true JP2019099571A5 (enExample) | 2022-01-06 |
| JP7461104B2 JP7461104B2 (ja) | 2024-04-03 |
Family
ID=66975925
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018223465A Active JP7461104B2 (ja) | 2017-11-29 | 2018-11-29 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| JP2024045935A Active JP7767492B2 (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| JP2025182210A Pending JP2026016628A (ja) | 2017-11-29 | 2025-10-29 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045935A Active JP7767492B2 (ja) | 2017-11-29 | 2024-03-22 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| JP2025182210A Pending JP2026016628A (ja) | 2017-11-29 | 2025-10-29 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP7461104B2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110618208A (zh) * | 2019-09-10 | 2019-12-27 | 威海迪素制药有限公司 | 一种（s）-（+）-3-羟基四氢呋喃对映异构体含量检测方法 |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| IL299704A (en) * | 2020-07-20 | 2023-03-01 | Eccogene Shanghai Co Ltd | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using them |
| CN116615430A (zh) * | 2020-09-07 | 2023-08-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4211139A4 (en) * | 2020-09-10 | 2024-12-18 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| LT4408840T (lt) | 2021-09-27 | 2025-10-10 | Benzimidazolo karboksilinės rūgštys kaip glp-1r agonistai | |
| WO2023076237A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JP2025508812A (ja) | 2022-02-23 | 2025-04-10 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒアゴニストとしての化合物 |
| EP4522129A1 (en) * | 2022-05-11 | 2025-03-19 | Eli Lilly And Co. | Glp1 pharmaceutical compositions |
| CR20240480A (es) * | 2022-05-11 | 2024-12-19 | Lilly Co Eli | Composiciones de comprimidos de glp1 |
| AU2023397781A1 (en) * | 2022-12-13 | 2025-06-26 | Eli Lilly And Company | Dosage regime of orforglipron for treating a subject with type 2 diabetes (t2d), obesity, or overweight with at least one weight related comorbidity |
| EP4634156A1 (en) * | 2022-12-15 | 2025-10-22 | Sironax Ltd | Sarm1 modulators, preparations, and uses thereof |
| KR20250121439A (ko) * | 2022-12-19 | 2025-08-12 | 일라이 릴리 앤드 캄파니 | Glp1 ra 및 그의 중간체의 제조 방법 |
| AU2024210933A1 (en) * | 2023-01-17 | 2025-08-07 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024211898A1 (en) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| WO2025002250A1 (zh) * | 2023-06-29 | 2025-01-02 | 韦恩生物科技有限公司 | 一种glp-1受体激动剂及其制备方法和用途 |
| CN120574225A (zh) * | 2023-06-30 | 2025-09-02 | 正大天晴药业集团股份有限公司 | 含多稠环结构的化合物 |
| CN121712771A (zh) * | 2023-07-28 | 2026-03-20 | 上海翰森生物医药科技有限公司 | 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025097835A1 (zh) | 2023-11-10 | 2025-05-15 | 重庆医药工业研究院有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| CN120136870A (zh) * | 2023-12-05 | 2025-06-13 | 信达生物科技有限公司 | 靶向glp-1受体的化合物以及其用途 |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
| WO2025209515A1 (zh) * | 2024-04-03 | 2025-10-09 | 广州市联瑞制药有限公司 | 一种glp-1受体激动剂及其制备方法和应用 |
| WO2025261454A1 (zh) * | 2024-06-19 | 2025-12-26 | 上海翰森生物医药科技有限公司 | 一种含氮大环化合物衍生物调节剂及其制备方法和应用 |
| WO2026001866A1 (zh) * | 2024-06-24 | 2026-01-02 | 联邦生物科技(珠海横琴)有限公司 | 一种glp-1受体激动剂及其应用 |
| WO2026012449A1 (zh) * | 2024-07-12 | 2026-01-15 | 联邦生物科技(珠海横琴)有限公司 | 一种具有glp-1受体激动剂效应的杂环化合物及其应用 |
| WO2026032183A1 (en) * | 2024-08-05 | 2026-02-12 | Rongchang Pharmaceuticals, Ltd. | Nitrogen-containing fused ring compound, pharmaceutical composition and use thereof |
| CN121627686A (zh) * | 2024-09-09 | 2026-03-10 | 中国科学院上海药物研究所 | 多环杂芳烃类glp-1受体激动剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2494700C (en) | 2002-08-26 | 2011-06-28 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
| EP2096923B1 (en) | 2006-11-27 | 2014-01-22 | H. Lundbeck A/S | Heteroaryl amide derivatives |
| MX2011010347A (es) | 2009-03-30 | 2011-11-29 | Transtech Pharma Inc | Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos. |
| EP2953681B1 (en) | 2013-02-06 | 2017-03-15 | Boehringer Ingelheim International GmbH | New indanyloxydihydrobenzofuranylacetic acids |
| EP2993174A1 (en) | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
-
2018
- 2018-11-29 JP JP2018223465A patent/JP7461104B2/ja active Active
-
2024
- 2024-03-22 JP JP2024045935A patent/JP7767492B2/ja active Active
-
2025
- 2025-10-29 JP JP2025182210A patent/JP2026016628A/ja active Pending